Investment
Features
FeesSafety
Academy
More
Pluang+

Compare e l f Beauty Inc (ELF) vs Eli Lilly And Co (LLY) Price & Performance

e l f Beauty IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

e l f Beauty Inc vs Eli Lilly And Co — how do they compare? e l f Beauty Inc trades at $76.34 (market cap $4.37B), while Eli Lilly And Co trades at $1,172.8 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 235.7× e l f Beauty Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals.

ELFLLY
Market Cap
$4.37B$1.03T
Sector
TechnologyHealth
52-Week High
$146.67$1.24K
52-Week Low
$49.57$625.65
Enterprise Value
$5.00B$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

e l f Beauty Inc

ELF Beauty trades at $76.11, up 5.34% with bullish technical signals and strong earnings beats. The stock shows robust revenue growth reaching $1.31B in 2025, though net margins remain thin at 1.61%. Recent analyst coverage is mixed with 46% buy ratings and consensus target of $74.42, slightly below current price. The company demonstrates solid operational cash flow of $133.84M and maintains a healthy balance sheet with $148.69M cash.

Outlook remains positive with continued double-digit sales growth targets, though elevated P/E ratio of 168.68 presents valuation concerns. Key risks include tariff exposure and core brand momentum challenges. Institutional sentiment leans bullish with recent price momentum supported by earnings outperformance and strategic expansion into skincare categories.

Eli Lilly And Co

LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.

Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About e l f Beauty Inc

e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.

Read more on ELF

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY